Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma (Nasdaq: RPRX) has announced its participation in two major healthcare investor conferences in December 2024. The company will present at the 7th Annual Evercore ISI HealthCONx Conference on December 3 at 12:55 p.m. ET, followed by Citi's 2024 Global Healthcare Conference on December 4 at 1:45 p.m. ET. Both presentations will be available via webcast on the company's investor relations website and will remain archived for at least thirty days.
Royalty Pharma (Nasdaq: RPRX) ha annunciato la sua partecipazione a due importanti conferenze per investitori del settore sanitario a dicembre 2024. L'azienda presenterà alla 7ª Conferenza Annuale Evercore ISI HealthCONx il 3 dicembre alle 12:55 ET, seguita dalla Conferenza Globale sulla Salute 2024 di Citi il 4 dicembre alle 13:45 ET. Entrambe le presentazioni saranno disponibili tramite webcast sul sito web delle relazioni con gli investitori della società e rimarranno archiviate per almeno trenta giorni.
Royalty Pharma (Nasdaq: RPRX) ha anunciado su participación en dos importantes conferencias de inversores en el sector de la salud en diciembre de 2024. La compañía presentará en la 7ª Conferencia Anual Evercore ISI HealthCONx el 3 de diciembre a las 12:55 p.m. ET, seguida de la Conferencia Global de Salud 2024 de Citi el 4 de diciembre a la 1:45 p.m. ET. Ambas presentaciones estarán disponibles en transmisión web en el sitio web de relaciones con inversores de la empresa y permanecerán archivadas por al menos treinta días.
로열티 파마 (Nasdaq: RPRX)는 2024년 12월 두 개의 주요 헬스케어 투자자 회의에 참여한다고 발표했습니다. 회사는 12월 3일 오후 12시 55분 ET에 제7회 에버코어 ISI 헬스컨넥스 콘퍼런스에서 발표한 후, 12월 4일 오후 1시 45분 ET에 씨티의 2024 글로벌 헬스케어 콘퍼런스에서 발표합니다. 두 프레젠테이션 모두 회사의 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며 최소 30일 동안 아카이브됩니다.
Royalty Pharma (Nasdaq: RPRX) a annoncé sa participation à deux grandes conférences pour investisseurs dans le domaine de la santé en décembre 2024. L'entreprise présentera lors de la 7e Conférence Annuelle Evercore ISI HealthCONx le 3 décembre à 12h55 ET, suivie de la Conférence Mondiale sur la Santé 2024 de Citi le 4 décembre à 13h45 ET. Les deux présentations seront disponibles en webdiffusion sur le site des relations investisseurs de l'entreprise et resteront archivées pendant au moins trente jours.
Royalty Pharma (Nasdaq: RPRX) hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Gesundheitswesen im Dezember 2024 angekündigt. Das Unternehmen wird am 3. Dezember um 12:55 Uhr ET auf der 7. jährlichen Evercore ISI HealthCONx-Konferenz präsentieren, gefolgt von der Citi Global Healthcare Conference 2024 am 4. Dezember um 13:45 Uhr ET. Beide Präsentationen werden über einen Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein und mindestens dreißig Tage lang archiviert bleiben.
- None.
- None.
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:
- 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3 at 12:55 p.m. ET
- Citi’s 2024 Global Healthcare Conference on Wednesday, December 4 at 1:45 p.m. ET
The webcasts will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. Webcasts will also be archived for a minimum of thirty days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
FAQ
When is Royalty Pharma (RPRX) presenting at the Evercore ISI HealthCONx Conference in December 2024?
What time is Royalty Pharma's (RPRX) presentation at Citi's 2024 Global Healthcare Conference?
How long will Royalty Pharma's (RPRX) December 2024 investor conference webcasts be available?